These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 14764524)
1. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Eslin DE; Zhang C; Samuels KJ; Rauova L; Zhai L; Niewiarowski S; Cines DB; Poncz M; Kowalska MA Blood; 2004 Nov; 104(10):3173-80. PubMed ID: 14764524 [TBL] [Abstract][Full Text] [Related]
2. Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Kowalska MA; Mahmud SA; Lambert MP; Poncz M; Slungaard A Blood; 2007 Sep; 110(6):1903-5. PubMed ID: 17540840 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of low-molecular-weight heparin reversal by platelet factor 4. Fiore MM; Mackie IM Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682 [TBL] [Abstract][Full Text] [Related]
4. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Rauova L; Zhai L; Kowalska MA; Arepally GM; Cines DB; Poncz M Blood; 2006 Mar; 107(6):2346-53. PubMed ID: 16304054 [TBL] [Abstract][Full Text] [Related]
6. Influence of platelet factor 4 on the neutralization of heparin by protamine. Shanberge JN; Quattrociocchi-Longe TM Ann N Y Acad Sci; 1989; 556():354-65. PubMed ID: 2735664 [TBL] [Abstract][Full Text] [Related]
7. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347 [TBL] [Abstract][Full Text] [Related]
8. Heparin neutralization by recombinant platelet factor 4 and protamine. Levy JH; Cormack JG; Morales A Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278 [TBL] [Abstract][Full Text] [Related]
9. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin. Shanberge JN; Quattrociocchi-Longe TM; Martens MH Thromb Res; 1987 Apr; 46(1):89-100. PubMed ID: 3590116 [TBL] [Abstract][Full Text] [Related]
10. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Reilly MP; Taylor SM; Hartman NK; Arepally GM; Sachais BS; Cines DB; Poncz M; McKenzie SE Blood; 2001 Oct; 98(8):2442-7. PubMed ID: 11588041 [TBL] [Abstract][Full Text] [Related]
11. The role of platelet factor 4 in radiation-induced thrombocytopenia. Lambert MP; Xiao L; Nguyen Y; Kowalska MA; Poncz M Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1533-40. PubMed ID: 21740995 [TBL] [Abstract][Full Text] [Related]
12. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Kowalska MA; Rauova L; Poncz M Thromb Res; 2010 Apr; 125(4):292-6. PubMed ID: 20004006 [TBL] [Abstract][Full Text] [Related]
13. Platelet factor 4 impairs the anticoagulant activity of activated protein C. Preston RJ; Tran S; Johnson JA; Ní Áinle F; Harmon S; White B; Smith OP; Jenkins PV; Dahlbäck B; O'Donnell JS J Biol Chem; 2009 Feb; 284(9):5869-75. PubMed ID: 19129181 [TBL] [Abstract][Full Text] [Related]
14. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Cook JJ; Niewiarowski S; Yan Z; Schaffer L; Lu W; Stewart GJ; Mosser DM; Myers JA; Maione TE Circulation; 1992 Mar; 85(3):1102-9. PubMed ID: 1537108 [TBL] [Abstract][Full Text] [Related]
15. Optimization of a murine immunization model for study of PF4/heparin antibodies. Suvarna S; Qi R; Arepally GM J Thromb Haemost; 2009 May; 7(5):857-64. PubMed ID: 19245419 [TBL] [Abstract][Full Text] [Related]
16. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density. Poon MC; Hurst RE; Rives MS Thromb Haemost; 1982 Apr; 47(2):162-5. PubMed ID: 7101237 [TBL] [Abstract][Full Text] [Related]
17. Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Cai Z; Yarovoi SV; Zhu Z; Rauova L; Hayes V; Lebedeva T; Liu Q; Poncz M; Arepally G; Cines DB; Greene MI Nat Commun; 2015 Sep; 6():8277. PubMed ID: 26391892 [TBL] [Abstract][Full Text] [Related]
18. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related]
19. Polycistronic expression of human platelet factor 4 with heparin-neutralizing activity in Escherichia coli. Duan Y; Wang Z; Wu W; Fang Z; Huang H Biosci Biotechnol Biochem; 2012; 76(10):1855-60. PubMed ID: 23047095 [TBL] [Abstract][Full Text] [Related]
20. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Rauova L; Poncz M; McKenzie SE; Reilly MP; Arepally G; Weisel JW; Nagaswami C; Cines DB; Sachais BS Blood; 2005 Jan; 105(1):131-8. PubMed ID: 15304392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]